Adverse Events for Treatment With Fosaprepitant Weekly vs Every 3 Weeks
nausea, xerostomia, dyspnea, fatigue, pain, insomnia, ill
ADVERSE EVENTS, APPETITE LOSS, XEROSTOMIA
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; NA, not applicable.No grade 4 or 5 adverse events occurred during treatment.Adherence rates of the quality-of-life questionnaires deteriorated during the CCRT, with 98% of the expected forms received at baseline, 90% at week 1, 87% at week 2, 88% at week 3, 82% at week 4, 80% at week 5, 73% at week 6, 26% at week 7, and 5% at week 8. Quality-of-life analyses showed that patients who received weekly fosaprepitant experienced less fatigue, nausea and vomiting, dyspnea, insomnia, and appetite loss and presented with better role function and emotional function compared with those who received fosaprepitant every 3 weeks. As for the symptoms and functions of the head and neck, patients receiving weekly fosaprepitant were found to have significantly less problems regarding pain, swallowing, sense, teeth, xerostomia, sticky saliva, coughing, feeling ill, and nutritional supplements (